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Introduction: The deposition of the amyloid β protein (Aβ) in the brain is a hallmark of Alzheimer's disease (AD).
Removal of Aβ by Aβ-antibody treatment has been developed as a potential treatment strategy against AD. First clinical
trials showed neither a stop nor a reduction of disease progression. Recently, we have shown that the formation of
soluble and insoluble Aβ aggregates in the human brain follows a hierarchical sequence of three biochemical
maturation stages (B-Aβ stages). To test the impact of the B-Aβ stage on Aβ immunotherapy, we treated transgenic
mice expressing human amyloid precursor protein (APP) carrying the Swedish mutation (KM670/671NL; APP23) with the
Aβ-antibody β1 or phosphate-buffered saline (PBS) beginning 1) at 3 months, before the onset of dendrite degeneration
and plaque deposition, and 2) at 7 months, after the start of Aβ plaque deposition and dendrite degeneration.
Results: At 5 months of age, first Aβ aggregates in APP23 brain consisted of non-modified Aβ (representing B-Aβ stage
1) whereas mature Aβ-aggregates containing N-terminal truncated, pyroglutamate-modified AβN3pE and phosphorylated
Aβ (representing B-Aβ stage 3) were found at 11 months of age in both β1- and PBS-treated animals. Protective effects
on commissural neurons with highly ramified dendritic trees were observed only in 3-month-old β1-treated animals
sacrificed at 5 months. When treatment started at 7 months of age, no differences in the numbers of healthy
commissural neurons were observed between β1- and PBS-treated APP23 mice sacrificed with 11 months.
Conclusions: Aβ antibody treatment was capable of protecting neurons from dendritic degeneration as long as Aβ
aggregation was absent or represented B-Aβ stage 1 but had no protective or curative effect in later stages with mature
Aβ aggregates (B-Aβ stage 3). These data indicate that the maturation stage of Aβ aggregates has impact on potential
treatment effects in APP23 mice.
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The deposition of the amyloid β-protein (Aβ) in senile
plaques is one of the hallmarks of Alzheimer’s disease
(AD) [1, 2]. Active and passive immunization against the
Aβ peptide has been developed to treat AD [3, 4]. In amyl-
oid precursor protein (APP) transgenic mice, peripheral
administration of Aβ-antibodies lead to a reduced number
of detectable plaques and prevented a further increase in
the number of detectable Aβ plaques [3, 5]. Even the* Correspondence: dietmar.thal@uni-ulm.de
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creativecommons.org/publicdomain/zero/1.0/amount of fibrillar, Thioflavin S-positive plaques was re-
duced in anti-Aβ treated animals [6]. However, another
group could not confirm Aβ reduction though an im-
provement of memory dysfunction was observed [7–9].
Active immunization in PDAPP mice demonstrated more
effective rescue from cognitive impairment when treat-
ment was started to prevent Aβ pathology compared to
mice treated at a later point in life in a reversal trial [10].
First trials of active and passive Aβ immunization in AD
patients, however, did not show a reduction of symptoms
or prevention from further disease progression [11–16].
Given the discrepancy between the reduction of stained
plaques and memory improvement in APP transgenic
mice and the clinical disease progression in AD patientsess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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AD patients because treatment was started too late after
the onset of morphologically detectable neurodegenera-
tion. Recently, we reported biochemical stages of Aβ
aggregate maturation (B-Aβ stages) in the course of pre-
clinical and symptomatic AD [17]. In addition to the most
abundant forms of Aβ, i.e. Aβ1–40 and Aβ1–42, posttrans-
lational modifications of Aβ have been identified in Aβ
aggregates, including N-terminal truncations and pyro-
glutamate modifications at residues 3 or 11 (AβN3pE and
AβN11pE) and phosphorylation at Serine residue 8 (pAβ)
[18–20]. The presence of AβN3pE, thereby, indicates
B-Aβ stage 2 and that of pAβ B-Aβ stage 3 [17]. It is not
yet clear whether the B-Aβ stage has impact on the ef-
fect of Aβ-antibody treatment and whether maturation
of Aβ aggregates explains the failure of treatment trials
in AD patients.
To address these questions in a mouse model we
chose APP23 mice, which overexpress human APP with
the Swedish mutation (KM670/671NL) driven by a Thy1
promoter [21]. These mice produce soluble and insol-
uble Aβ aggregates, Aβ plaques and they show neuron
loss in CA1, loss of asymmetric synapses in the fronto-
central neocortex [22, 23] as well as more subtle degen-
eration of a subtype of layer III commissural neurons in
the frontocentral neocortex, i.e. the degeneration of
commissural neurons with a highly ramified dendritic
tree. Degeneration of these highly ramified commissural
neurons was seen as early as at 5 months of age in paral-
lel with the onset of Aβ plaque deposition whereas no
such changes were reported at 3 months of age in the
absence of Aβ aggregates [24]. Degeneration of axons of
commissural neurons represents the morphological cor-
relative for corpus callosum atrophy, which is an early
event in the pathogenesis of AD [25–27]. As such, these
mice showing early degeneration of commissural neurons
are ideally suited to study the effects of Aβ-antibody treat-
ment on these Aβ-related neurodegenerative changes.
In this study, we treated APP23 mice with the Aβ-
antibody β1 (Additional file 1: Table S1) beginning 1) at
3 months of age before the onset of plaque deposition
and degeneration of commissural neurons and 2) at
7 months of age after plaque deposition and neurodegen-
eration started. The β1 antibody is directed against the N-
terminus of Aβ and capable of preventing Aβ deposition
in APP23 mice when it is transgenetically expressed [28].
The treated animals were sacrificed and the samples were
analyzed 1) with 5 months - when first plaques and early
dendrite degeneration can be identified in APP 23 mice
- to detect protective effects and 2) with 11 months to
clarify whether β1 antibody treatment allows recovery
of altered highly ramified commissural neurons after a
4-month-treatment period. PBS-treated animals were
used as controls.Material and methods
Animals
APP23 mice were generated as described previously [21]
and continuously back-crossed to C57BL/6. The murine
Thy-1 cassette was used to drive neuron-specific expres-
sion of human APP751 with the Swedish double muta-
tion 670/671 KM→NL. Heterozygous female APP23
mice of two age groups, 3 months (n = 44) and 7 months,
(n = 39) were treated in this study and analyzed at 5 and
11 months of age, respectively. Animals were treated in
agreement with German and Swiss laws on the use of la-
boratory animals.
Vaccination
Passive vaccination was performed in APP23 mice by
weekly intraperitoneal (i.p.) injections of 500 μg of β1-
anti-Aβ antibody [29] (Additional file 1: Table S1). As
control group, APP23 mice received weekly i.p. injec-
tions of phosphate-buffered saline (PBS).
3-month-old animals were treated for 9 weeks, until
5 months of age, and were sacrificed 2–3 days after the
last injection (β1: n = 21, PBS: n = 23). 7-month-old mice
received injections for 12 weeks, until the age of 11 months,
and were sacrificed for analysis 5–6 days after the last in-
jection (β1: n = 21, PBS: n = 18). Animal experiments were
carried out with permission of the Regierungspräsidium
Tübingen/Germany (Permission: Animal Experiment No.
933) and the Animal Care and Use Committees of the
Kanton Basel, Switzerland (Permission 1980).
Tissue preparation and DiI tracing
For DiI tracing and histopathological examinations, the
brains of 5 and 11-months-old β1-treated and PBS-treated
animals were used (5 months – β1: n = 9, PBS: n = 10;
11 months – β1: n = 10; PBS: n = 10). Mice were anesthe-
tized and perfusion was performed transcardially with
Tris-buffered saline (TBS) with heparin (pH 7.4) followed
by the injection of 0.1 M PBS (pH 7.4) containing 2.6 %
paraformaldehyde (PFA), 0.8 % iodoacetic acid, 0.8 % so-
dium periodate and 0.1 M D-L lysine. The brains were re-
moved in total and post-fixed in 2.6 % phosphate-buffered
PFA (pH 7.4) containing 0.8 % iodoacetic acid, 0.8 % so-
dium periodate and 0.1 M D-L lysine [30]. After 3 days, a
single crystal (0.3 mm3) of the carbocyanine dye DiI (Mo-
lecular Probes, Eugene, OR, USA) was implanted into the
left frontocentral cortex, 1 mm rostrally from the central
sulcus, 2 mm laterally from the middle line and 1 mm
deep in the cortex as reported earlier [24]. This dye allows
precise Golgi-like tracing of neurons in post-mortem fixed
tissue in a quality similar to in-vivo tracing methods
[24]. After incubation in 2.6 % phosphate-buffered PFA
for at least 3 months at 37 °C, 100 μm thick coronal
vibratome sections were cut. All sections of a given
mouse brain were separately stored and continuously
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Microscopic and quantitative analysis
In layer III of the frontocentral cortex of the right hemi-
sphere, contralateral to the implantation site of the
tracer, the morphology of traced commissural neurons
was examined. The traced neurons were assigned to
different types according to their morphology [24]
(Additional file 2: Table S2). Then the number of traced
commissural neurons of each type in β1-treated APP23
mice was counted and compared with that in PBS-treated
APP23 mice. For qualitative and quantitative analysis, 10
consecutive sections (100-μm thickness each) representing
a tissue block of 1 mm thickness were studied for each
mouse. Analysis started at the anterior commissure setting
the caudal limit of the investigated tissue block. For each
coronal section, the medial boundary of the region investi-
gated was set as the vertical line at the cingulum that sep-
arated the cingulate cortex from secondary motor cortex
(M2). The horizontal boundary was set as the horizontal
line separating the primary somatosensory cortex (S1)
from the insular cortex.
For the qualitative analysis, a laser scanning confocal
microscope (Leica TCS NT, Leica, Bensheim, Germany)
was used. Stacks of 2D images were superimposed digit-
ally using the ImageJ image processing and analysis
software (National Institutes of Health (NIH), Bethesda,
MD, USA), and 3D data sets were generated for the
visualization of neurons with their entire dendritic tree.
For quantification, traced neurons in layer III were
counted in the region of interest in 10 consecutive sec-
tions of the tissue block taken for qualitative and quanti-
tative analysis using a fluorescence microscope (Leica
DMLB, Leica, Germany). In so doing, we analyzed a cor-
tex volume of 5–6 mm3 in each mouse. Mean and
median values of the number of traced neurons were
calculated and compared between β1-treated and PBS-
treated APP23 mice of a given age.
Immunohistochemistry
Morphological and immunohistochemical analysis were
carried out on sections of the traced animals after
obtaining the tracing results. Vibratome sections of the
frontocentral cortex were immunostained with anti-
Aβ17–24, anti-Aβ1–17, anti-Aβ42, anti-Aβ40, anti-AβN3pE,
anti-pAβ, anti-Aβ-β1, anti-APP, anti-mouse-IgG, anti-
glial fibrillary acidic protein (GFAP) and the microglia
marker iba-1 [18, 19, 29, 31, 32] (Additional file 1: Table
S1). The primary antibodies were detected with the re-
spective biotinylated anti-mouse and anti-rabbit IgG sec-
ondary antibodies and visualized with the ABC-complex
(ABC-Kit, Vector Laboratories, Burlingame, CA, USA)
and diaminobencidine-HCl (DAB) as chromogen. Toavoid crossreactivity of intrinsic IgG with anti-mouse-
IgG secondary antibodies, sections were preincubated
with goat-anti-mouse-IgG [33]. Protofibrils and fibrils
were detected with B10AP-antibody fragments coupled
with alkaline phosphatase [34]. They were visualized
with permanent red (DAKO, Glostrup, Denmark). For
immunofluorescence, rabbit primary antibodies were de-
tected with carbocyanine 3 (Cy3)-labeled anti-rabbit-IgG
secondary antibodies whereas mouse IgG was detected
with Cy2-labeled anti-mouse IgG antibodies without
previous anti-mouse-IgG blocking to allow the detection
of intrinsic IgGs. Amyloid material was identified in the
double stained section by UV-light-induced amyloid
autofluorescence, i.e. detection of unstained amyloid
material by fluorescence microscopy (excitation filter:
360–370 nm; emission filter: > 420 nm) [35]. Respective
positive and negative controls were performed.
Quantification of plaque loads for Aβ42-, Aβ40-, AβN3pE-,
pAβ-, β1- and B10AP-positive plaques
Aβ42 load was determined as the percentage of the area
in the frontocentral cortex covered by Aβ plaques de-
tected with anti-Aβ42 antibodies. Morphometry for
Aβ42 load determination was performed using ImageJ
image processing and analysis software by interactive
measurement of plaque areas in a region of interest as
well as of the total area of interest. The plaque load was
calculated as the percentage of the area of interest
covered by amyloid plaques stained with the antibody
(National Institutes of Health, Bethesda, USA) [23].
Accordingly, the Aβ40, AβN3pE, pAβ, Aβ1–17, β1 and
B10AP loads were determined as the percentage of the
frontocentral cortex area covered by plaques positive
for the respective antibodies.
Protein extraction from brain tissue and serum
For biochemistry, deeply anesthetized mice were sacri-
ficed by decapitation. Blood was collected after decapita-
tion. Serum was isolated after centrifugation at 3000 × g
for 30 min at room temperature. Serum samples were
immediately frozen at −80 °C until the performance of
the experiments. The brains were taken, dissected, and
unfixed left and right hemispheres as well as the brain
stem and the cerebellum were kept separately at −80 °C
for further analysis.
Protein extraction from frozen brain samples of 5- and
11-month-old APP23 treated with β1-antibodies (5 months:
n = 12, 11 months: n = 11) or PBS (5 months: n = 13,
11 months: n = 8) was carried out for biochemical studies
[17, 23]. Briefly, fresh frozen forebrain tissue samples
(0.4 g) were homogenized in 2 ml of 0.32 M sucrose dis-
solved in Tris-buffered saline (TBS) containing a protease
and phosphatase inhibitor-cocktail (Complete and Phos-
STOP, Roche, Mannheim, Germany) with Micropestle
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The homogenate was centrifuged for 30 min at 14,000 × g
at 4 °C. The supernatant (S1), containing both the soluble
and dispersible fraction was kept for further ultracentri-
fugation. The pellet (P1) containing the membrane-
associated and the insoluble, plaque-associated fraction
was resuspended in 2 % SDS. Ultracentrifuging of the
supernatant S1 at 175,000 × g was used to separate the
soluble, i.e. the supernatant after ultracentrifuging (S2),
from the dispersible fraction, i.e. the resulting pellet
(P2). The pellet P2 with the dispersible fraction was re-
suspended in TBS.
The SDS-resuspended pellet P1 was centrifuged at
14,000 × g the supernatant (S3) was kept as membrane-
associated SDS-soluble fraction. The pellet (P3) that
remained was dissolved in 70 % formic acid and dried in
a vacuum centrifuge (Vacufuge, Eppendorf, Hamburg,
Germany) and reconstituted in 100 μl of 2X LDS (lith-
ium dodecyl sulfate) sample buffer (Life Technologies,
Carlsbad, CA, USA) followed by heating at 70 °C for
5 min. The resultant sample was considered as insoluble,
plaque-associated fraction [36]. The total protein amounts
of soluble, dispersible, and membrane-associated fractions
were determined using BCA Protein Assay (Bio-Rad,
Hercules, CA, USA).
Immunoprecipitation
For immunoprecipitation (IP), 200 μl of the native sol-
uble and dispersible fractions from the brain lysates were
incubated with 1 μl A11 antibodies against non-fibrillar
oligomers, or 5 μl B10AP antibody fragments for precipi-
tation of protofibrils and fibrils (Additional file 1: Table
S1) or were kept without adding antibodies to identify
already antibody-bound Aβ. 50 μl of protein G-coated
Microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany)
were added to the mixture and incubated overnight at 4 °C.
The mixture was then passed through the μColumns,
which separate the microbeads by retaining them in the
column, while the rest of the lysate flows through. After
one mild washing step with 1X TBS at pH 7.4 the
microbead-bound-proteins were eluted with 95 °C heated
1X LDS sample buffer (Life Technologies, Carlsbad,
CA, USA).
SDS-PAGE and Western blot analysis
For SDS-PAGE, soluble (S2), dispersible (P2), membrane-
associated (SDS-soluble; S3), insoluble, plaque-associated
(formic acid soluble; P3) fractions and IP eluates (50 μg
total protein) were electrophoretically resolved in a pre-
cast NuPAGE 4–12 % Bis-Tris gel system (Life Technolo-
gies, Carlsbad, CA, USA). Proteins were transferred onto
Nitrocellulose membrane and membranes were boiled in
1X PBS for 5 min. The protein load was controlled ei-
ther by Ponceau S staining (C4, 1/1000, Santa CruzBiotechnology, Santa Cruz, CA, USA) or by MemCode
reversible protein stain kit (Pierce, Rockford, IL, USA)
prior to immunoblotting.
Aβ was detected by western blotting with anti-Aβ1–17,
anti-pAβ and anti-AβN3pE antibodies (Additional file 1:
Table S1). Blots were incubated with chemiluminescent
ECL detection system (Supersignal Pico Western system,
ThermoScientific-Pierce, Waltham, MA, USA) or Lumi-
nata Forte Western HRP substrate (Merck Millipore,
Billerica, Massachusetts, USA) and acquired using either
ECL Hyperfilm (GE Healthcare, Buckinghamshire, UK)
or CCD imager Image Quant LAS 4000 (GE Healthcare,
Buckinghamshire, UK). Since anti-Aβ1–17 also stains APP
we used the respective protein bands corresponding to
~110 kDa seen with this antibody as internal loading con-
trol to verify the protein content.
Because Aβ aggregates readily dissociate in the pres-
ence of SDS-containing buffers into monomers and
small oligomers, such as dimers, trimers, or Aβ*56 [37,
38], we analyzed differences among the monomer bands
that indicate changes in the protein levels of precipitated
Aβ aggregates densitometrically using ImageJ software
(NIH, Bethesda, MD, USA). This method allows a semi-
quantitative assessment of Aβ [23]. Briefly, the X-ray
films were scanned and image colors were inverted or
the images acquired by CCD imager were exported as 8-
bit grayscale TIFF files. The relative protein levels of the
monomer bands were measured as integrated density
values for each lane [39].
Biochemical stages of Aβ aggregation (B-Aβ stages)
were determined on the basis of Aβ, AβN3pE and pAβ
detection in the soluble, dispersible, membrane-associated,
and plaque-associated fraction [17]: B-Aβ stage 1 =Aβ ag-
gregates detected only with anti-Aβ1–17; B-Aβ stage 2 = Aβ
aggregates positive for anti-Aβ1–17 and anti-AβN3pE but not
for anti-pAβ; B-Aβ stage 3 = Aβ aggregates containing
anti-Aβ1–17-, anti-AβN3pE- and anti-pAβ-positive material.
Stereology
Six β1-treated and six PBS-treated APP23 mice at the
ages of 5 and 11 months, respectively, were chosen ran-
domly for stereology. One brain section including the
hippocampal formation already quantified for the num-
ber of DiI-traced neurons was selected by chance and
stained with aldehyde fuchsin-Darrow red. Quantification
of neurons was performed according to the principles of
unbiased stereology [40]. The CA1 volume was measured
in serial 100 μm thick sections of the entire mouse brain
at 5 × magnification. Neurons were counted in three dif-
ferent, randomly chosen microscopic fields (40 × objective
magnification) of an aldehyde fuchsin – Darrow red
stained section of the frontocentral cortex and CA1, re-
spectively. For optical dissection, stacks of 10 images in
2 μm focus distance were generated for each microscopic
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round nucleoli visible in the center of soma in one of the
stack-images were considered for quantification using the
ImageJ software (NIH, Bethesda, USA). The number of
neurons in the frontocentral cortex and CA1 was calcu-
lated on the basis of the respective reference volumes and
neuron densities as previously published [41].
Electron microscopy, immunoelectron microscopy and
semiquantitative assessment of synapse densities
100 μm thick vibratome sections of the frontocentral
cortex from six β1-treated and six PBS-treated APP23
mice, aged 5 and 11 months, respectively, were flat-
embedded in Epon (Fluka, Germany). A part of the of
the frontocentral cortex covering all six layers was cut
and pasted on a second Epon block ultrathin sections
were cut at 70 nm. Epon sections were block stained
with uranyl acetate and lead citrate, and viewed with a
Zeiss EM10 (Zeiss, Oberkochen, Germany), or a JEM-
1400 (JEOL, Tokyo, JP) electron microscope. Digital pic-
tures were taken.
Synaptic densities in the frontocentral cortex were
measured in 20 randomly taken pictures of the layers II-
VI at 4600-times magnification. The numbers of the
symmetric and asymmetric synapses were counted and
the length of the synapses was determined with the Ima-
geJ software (NIH, Bethesda, USA). The synaptic dens-
ity was determined separately for symmetric and
asymmetric synapses according to DeFelipe et al. [42]
(synaptic density = number of synapse-profiles in a
given area / length of synaptic profiles). These semi-
quantitative data were used to compare the synaptic
densities between the different mouse lines. Asymmetric
and symmetric synapses were distinguished according
to published criteria [43, 44].
Statistical analysis
SPSS 21.0 (SPSS, Chicago, IL, USA) software was used
to calculate statistical tests. Non-parametric tests were
used to compare β1-treated and PBS-treated APP23
mice. p-values were corrected for multiple testing using
the Bonferroni-method. Parametric data were analyzed
by ANOVA with subsequent Games-Howell post-hoc
test to correct for multiple testing or by using the Welch
test. The results of the statistical analysis are summa-
rized in Additional file 3: Table S3.
Results
Neurodegeneration in β1-treated and PBS-treated APP23
mice
Between 3 and 5 months of age degeneration of den-
drites of DiI-traced highly ramified commissural layer III
neurons in the frontocentral cortex was observed in β1-
treated as well as in PBS-treated animals (Fig. 1).However, β1-treated mice showed slightly higher num-
bers of type I commissural neurons than PBS-treated an-
imals (Mann-Whitney U-test: p < 0.05). The numbers of
type II and III commissural neurons did not differ be-
tween β1- and PBS-treated animals (Fig. 1 and Additional
file 3: Table S3). Treatment with the β1-antibody between
7 and 11 months of age had no obvious effect on the
numbers of type I, II and III layer III commissural neurons
traced in the frontocentral neocortex in comparison to
PBS-treated controls (Fig. 1 and Additional file 3: Table
S3a).
Significant differences in the synapse densities of
asymmetric and symmetric synapses in the frontocentral
cortex as well as differences in the numbers of CA1 neu-
rons were not observed between β1-treated and PBS-
treated animals in both age groups (Additional file 3:
Table S3b, c and Additional file 4: Figure S1).
Aβ plaques in β1-treated and PBS-treated APP23 mice
Aβ plaques detectable with antibodies directed against
Aβ42, Aβ40, Aβ17–24, Aβ1–17, AβN3pE, and pAβ were
found in both, β1-treated and PBS-treated APP23 mice
(Figs. 2 and 3), without quantitative differences at 5 and
11 months of age, respectively (Additional file 3: Table
S3d). At 5 months of age only single plaques in some of
the mice were observed whereas in 11-month-old APP23
mice moderate numbers of plaques were seen. Further
analysis of 11-month-old animals using the β1 antibody
(used for passive immunization) showed that treated ani-
mals exhibited fewer plaques stained with β1 indicating
epitope masking (Fig. 3 and Additional file 3: Table S3d).
B10AP-positive plaques were also reduced in β1-treated
11-month-old animals (Fig. 3) whereas 5-month-old mice
did not exhibit B10AP-positive plaques regardless of β1
treatment (Additional file 3: Table S3d). APP-positive dys-
trophic neurites were seen in APP-type neuritic plaques
(i.e. amyloid plaques associated with APP-positive dys-
trophic neurites) of β1-treated and PBS-treated APP23
mice (Additional file 5: Figure S2). Mouse IgG was not
observed in plaques of 5-month-old animals whereas
amyloid plaques in 11-month-old β1- and PBS-treated
mice exhibited IgG in similar amounts (Additional
file 6: Figure S3 and Additional file 7: Figure S4).
Plaque-associated astrocytes and microglial cells were
seen in both β1- and PBS-treated APP23 mice at
11 months of age whereas no glial reaction was evident
in 5-month-old animals (Additional file 6: Figure S3 and
Additional file 7: Figure S4).
Brain Aβ, AβN3pE, and pAβ in β1-treated and PBS-treated
APP23 mice
Western blot analysis of forebrain homogenates revealed
no obvious differences in the amounts of soluble, dis-
persible, and membrane-associated Aβ detectable with
Fig. 1 Degeneration of commissural neurons with a highly ramified dendritic tree: Effects of β1 antibody treatment. a, b Layer III type 1
commissural neurons in the frontocentral cortex traced with DiI. The detectable type 1 commissural neurons did not show significant differences
between PBS- and β1-treated APP23 mice even at 5 months of age. c The number of the type 1 commissural neurons in 5-month-old β1 treated
mice was higher than that in PBS-treated animals whereas no such differences were observed for type 2 and 3 commissural neurons. d No
differences in the numbers of DiI-traced type 1–3 commissural neurons were seen among 11-month-old PBS- and β1-treated APP23 mice. Graphs
represent mean values (symbols) and standard errors (whiskers), * p < 0.05 (Statistical analysis in Additional file 3: Table S3). Calibration bar in
b (valid for a, b) = 37.5 μm
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both age groups (at 5 and 11 months of age). β1-treated
5-month-old APP23 mice exhibited higher amounts of
anti-Aβ1–17 detected plaque-associated Aβ than PBS-
treated animals (Fig. 4, Additional file 3: Table S3e and
Additional file 8: Figure S5). In 11-month-old mice, Aβ
in all four fractions was elevated in comparison to
5-month-old APP23 mice. Differences between the
treatment groups were not obvious at this age (Fig. 4,
Additional file 3: Table S3e and Additional file 8: Figure
S5). AβN3pE and pAβ were not observed in brain ho-
mogenates of 5-month-old animals but in mice of
11 months of age. No differences in the pattern of
AβN3pE and pAβ aggregation between β1- and PBS-
treated animals were seen (Fig. 4, Additional file 3: Table
S3e and Additional file 8: Figure S5). In accordance with apreviously published hierarchical pattern of Aβ aggregate
maturation during the course of AD, the presence of Aβ
in the absence of biochemically detectable AβN3pE and
pAβ in 5-month-old APP23 mice corresponded to B-Aβ
stage 1 whereas Aβ aggregates in 11-month-old mice con-
sisting of normal Aβ, AβN3pE, and pAβ were referred to as
B-Aβ stage 3 [17].
In 5-month-old mice, immunoprecipitation with the
oligomer-specific A11 antibody and with protofibril- and
fibril-specific B10AP antibody fragments and subsequent
western blot analysis with anti-Aβ1–17 showed more Aβ
oligomers, protofibrils and fibrils in the β1-treated group
compared to the PBS-treated group selectively in the
soluble fraction (Fig. 5, Additional file 3: Table S3 and
Additional file 9: Figure S6). Such a difference was not
found in 11-month-old animals. In the dispersible fractions
Fig. 2 Aβ plaque pathology in the frontocentral cortex of APP23 mice: Effects of β1 antibody treatment. Aβ plaque pathology in PBS- and
β1-treated APP23 mice. The staining pattern in 11-month-old mice as well as the plaque loads at 5 and 11 months of age did not differ between
PBS- and anti-Aβ (β1) treated animals when staining the plaques with antibodies raised against Aβ42 (a–c), Aβ40 (d–f), AβN3pE (g–i), and pAβ (j–l).
Graphs c, f, i, and l represent mean values (symbols) and standard errors (whiskers). (Statistical analysis see Additional file 3: Table S3). Calibration
bar in a (valid for a, b, d, e, g, h, j, k) = 280 μm
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protofibrils and fibrils between the β1-treated and PBS-
treated animals of both age groups (Fig. 5, Additional
file 3: Table S3f and Additional file 9: Figure S6).
In 5-month-old APP23 mice, irrespective of the treat-
ment, no AβN3pE and no pAβ was detected, in the soluble
and dispersible fraction of samples immunoprecipitated
with A11 or B10AP. Similarly, in 11-month-old mice,
AβN3pE and pAβ were not detected in A11 and B10AP
immunoprecipitated oligomers, protofibrils and fibrils
from the soluble fraction. AβN3pE and pAβ were found in
the dispersible fraction in Aβ protofibrils and fibrilsprecipitated with B10AP at 11 months of age but without
significant differences among β1- and PBS-treated animals
(Fig. 5, Additional file 3: Table S3f and Additional file 9:
Figure S6). There was no detectable AβN3pE in both
groups of 11-month-old mice in the dispersible fractions
immunoprecipitated with non-fibrillar Aβ oligomer-
specific A11 antibodies but pAβ was observed in β1- and
PBS-treated mice (Fig. 5, Additional file 3: Table S3f and
Additional file 9: Figure S6).
Immunoprecipitation of antibody-bound Aβ by incu-
bation of the brain samples with protein G magnetic
beads without previous coupling to primary antibodies
Fig. 3 Epitope masking effects of β1 antibody treatment in the frontocentral cortex of APP23 mice. Epitope modification after anti-Aβ (β1)
antibody treatment in 11-month-old APP23 mice. Although an antibody raised against Aβ1–17 (6E10) exhibited similar levels of Aβ plaques
(a, b - arrows) as provided by the respective Aβ (6E10) plaque load (c) the β1 antibody used for treatment detected less plaques in the treated
animals than in the PBS-controls (d, e - arrows) as confirmed by a significantly lowered β1 plaque load (f). Less plaques were also detected with
B10AP antibody fragments detecting protofibril/ fibril-specific epitopes (g, h - arrows) with respective changes in the B10AP plaque load (i).
Graphs c, f, and i represent mean values (symbols) and standard errors (whiskers), * p < 0.05 (Statistical analysis in Additional file 3: Table S3).
Calibration bar in a (valid for a, b, d, e, g, h) = 280 μm
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mice detected with anti-Aβ1–17 antibodies, but not in
PBS-treated animals (Fig. 6, Additional file 3: Table S3 and
Additional file 10: Figure S7). Such a difference was not
observed in 11-month-old mice. No soluble IgG-bound
AβN3pE and pAβ was seen in 5- and 11-month-old APP23
mice (Fig. 6). In the dispersible fractions, immunoprecipi-
tation with protein-G coated magnetic beads without pri-
mary antibody exposure and subsequent western blotting
with anti-Aβ1–17 antibodies, showed detectable amounts
of IgG-bound Aβ in both age and treatment groups, re-
spectively, without significant differences among treat-
ment (Fig. 6, Additional file 3: Table S3g and Additional
file 10: Figure S7). AβN3pE was not seen in antibody-
bound aggregates (Fig. 6, Additional file 3: Table S3g and
Additional file 10: Figure S7). In 5-month-old APP23 mice
no dispersible pAβ was observed in antibody-bound ag-
gregates but 11-month-old animals exhibited dispersible
pAβ in the precipitates without significant differencesbetween the treatment groups (Fig. 6, Additional file 3:
Table S3g and Additional file 10: Figure S7).Detection of Aβ in the blood serum of β1-treated and
PBS-treated APP23 mice
Western blot analysis did not reveal detectable amounts
of Aβ in the serum of 5- and 11-month-old β1- and
PBS-treated APP23 mice (Fig. 7 and Additional file 11:
Figure S8). Only after immunoprecipitation of antibody-
bound Aβ from blood serum using protein-G coated
magnetic beads without previous primary antibody
coupling showed anti-Aβ1–17 detectable Aβ in β1-treated
11-month-old APP23 mice but not in PBS-treated animals
(Fig. 7, Additional file 3: Table S3 and Additional file 11:
Figure S8). This effect was not observed at 5 months of
age. Antibody-bound AβN3pE and pAβ were not found in
the blood serum of APP23 mice of both ages regardless of
β1-treatment (Fig. 7 and Additional file 11: Figure S8).
Fig. 4 Soluble, dispersible, membrane-associated, and plaque-associated Aβ in APP23 mice: Effects of β1 antibody treatment. Semiquantitative
comparison of Aβ, AβN3pE, and pAβ in the soluble, dispersible, membrane-associated, and plaque-associated fraction of brain homogenates of
PBS- and β1-treated 5- and 11-month-old APP23 mice received by quantification of western blots displayed in Additional file 8: Figure S5. No
differences between PBS- and β1-treated animals except for plaque-associated Aβ in 5-month-old mice: β1-treated animals exhibited slightly
more non-modified plaque-associated Aβ than non-treated mice. AβN3pE and pAβ were not detected in brain homogenates of 5-month-old
APP23 mice but in the dispersible, membrane-associated, and plaque-associated fraction of 11-month-old mice without differences in relation
to the treatment. Graphs represent mean values (white symbols 5-month-old mice; black symbols 11-month-old mice) and standard errors
(whiskers). (* p < 0.05; detailed Statistical analysis in Additional file 3: Table S3)
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Our study on β1-immunized APP23 mice in comparison
to non-immunized mice revealed five major findings
(Fig. 8): 1. A qualitative change of Aβ aggregate compos-
ition was observed between 5- and 11-month-old APP23
mice corresponding with the biochemical maturation of
Aβ aggregates as also seen in human AD brain. 2.
Passive immunization with β1 antibodies starting at
3 months of age prior to the onset of Aβ deposition and
dendritic degeneration until 5 months of age provided a
protective effect against dendritic degeneration. Such an
effect was not seen when immunization started later at
7 months of age when plaques and dendritic degenerationwere already present. 3. Soluble antibody-bound oligo-
meric, protofibrillar and fibrillar Aβ-containing aggregates
were found in β1-treated 5-month-old APP23 mice but
not in PBS-treated mice. In older animals soluble
antibody-bound Aβ was observed in similar amounts
in both β1- and PBS-treated APP23 mice. 4. Aβ
immunization in animals with preexisting Aβ pathology
showed epitope masking effects in Aβ plaques but no
biochemically detectable differences of Aβ in the brain
between β1- and PBS-treated mice. 5. An increase of
antibody-bound non-modified Aβ in the blood serum,
but not of antibody-bound AβN3pE and pAβ was de-
tected in β1-treated APP23 mice.
Fig. 5 Soluble and dispersible (insoluble) Aβ fibrils/protofibrils and non-fibrillar oligomers in APP23 mice: Effects of β1 antibody treatment.
Semiquantitative analysis of western blots from soluble and dispersible non-fibrillar oligomers immunoprecipitated with A11 and protofibrils and
fibrils immunoprecipitated with B10AP from the respective brain homogenate fractions in 5- and 11-month-old β1- and PBS-treated APP23 mice.
5-month-old β1-treated mice exhibited soluble Aβ-oligomers, protofibrils and fibrils that were not seen in PBS-treated controls (* p < 0.05; detailed
statistical analysis in Additional file 3: Table S3). Although dispersible Aβ oligomers, protofibrils and fibrils occurred in 5-month-old APP23 mice as
well there were no differences between β1- and PBS-treated mice. AβN3pE and pAβ were not seen in 5-month-old mice. No differences in soluble
and dispersible Aβ aggregates were observed between 11-month-old β1- and PBS-treated mice. AβN3pE and pAβ were not detectable in soluble
oligomers, protofibrils and fibrils as well as in dispersible oligomers at both ages whereas dispersible fibrils and protofibrils exhibited both AβN3pE
and pAβ. Graphs represent mean values (white symbols 5-month-old mice; black symbols 11-month-old mice) and standard errors (whiskers). (Full
blots Additional file 9: Figure S6; Statistical analysis Additional file 3: Table S3)
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treatment with the β1-antibody is most effective in early
stages of Aβ aggregate maturation whereas late stage
aggregates containing AβN3pE and pAβ may preclude
sufficient clearance. In the following paragraphs, we dis-
cuss the hypothesis that biochemical maturation of Aβ
aggregates modifies its response to antibody treatment
in detail.
Protective effects of β1-antibody treatment in APP23
mice without preexisting pathology (Fig. 8)
Our study showed that β1 Aβ antibody treatment pro-
tected APP23 mice from severe dendrite degeneration intype 1 commissural neurons when treatment was started
at 3 months before Aβ and dendrite pathology develop
in this mouse model [24]. Such an effect was not ob-
served when treatment was started later, i.e. after the
onset of Aβ plaque pathology and type 1 commissural
neuron degeneration with 7 months of age. This finding
is in line with a previous report showing the absence of
beneficial effects after γ-secretase treatment in mice with
preexisting plaques [45]. The fact that only tracing of
commissural neurons revealed differences between β1-
and PBS-treated APP23 mice but neither CA1 neuron
numbers nor synapse densities in the frontocentral cor-
tex as further markers for neurodegeneration appear to
Fig. 6 Immunoglobulin-bound Aβ detected in oligomers, protofibrils and fibrils in APP23 mice: Effects of β1 antibody treatment. Semiquantitative
analysis of western blots after immunoprecipitation of immunoglobulin (antibody)-bound Aβ by precipitation of antibodies with protein G-coated
magnetic beads. Subsequent western blot analysis with anti-Aβ1–17 revealed antibody-bound Aβ in the dispersible fraction of both β1- and
PBS-treated mice at both ages. In 5-month-old β1-treated APP23 mice antibody-bound Aβ was found in the soluble fraction whereas no
antibody-bound Aβ was precipitated in PBS-treated animals (* p < 0.05). At 11-months of age both, β1 and PBS-treated animals exhibited
antibody bound soluble Aβ in similar amounts. Antibody-bound AβN3pE was not observed whereas 11-month-old (but not 5-month-old) APP23
mice showed similar amounts of dispersible antibody-bound pAβ. No soluble antibody-bound pAβ was seen. Graphs represent mean values
(white symbols 5-month-old mice; black symbols 11-month-old mice) and standard errors (whiskers). (Full blots Additional file 10: Figure S7;
Statistical analysis in Additional file 3: Table S3)
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neurons differ with respect to their vulnerability to
Aβ-related neurodegeneration in APP23 mice [24] and
the type 1 commissural neurons are among the most
vulnerable neurons in the frontocentral neocortex.Accordingly, degeneration of these neurons is a very
sensitive indicator for Aβ-induced neurodegeneration in
the APP23 mouse model that allows the detection of dif-
ferences in Aβ-related neurodegeneration before other
readouts such as synapse densities and neuron numbers
Fig. 7 Serum Aβ immunoprecipitated by protein-G bound antibodies in APP23 mice: Effects of β1 antibody treatment. Semiquantitative assessments
of western blot analysis of blood serum for Aβ and immunoprecipitation of intrinsic serum antibodies by incubation with protein G-coated magnetic
beads and with subsequent western blotting for Aβ. Aβ was only seen in 5-month-old β1-treated APP23 mice after antibody-immunoprecipitation
and detection with anti-Aβ1–17 (6E10) (* p < 0.05). AβN3pE and pAβ were not found in these precipitates. PBS-treated and 5-month-old mice did not
exhibit detectable amounts of Aβ. Graphs represent mean values (white symbols 5-month-old mice; black symbols 11-month-old mice) and standard
errors (whiskers). (Full blots Additional file 11: Figure S8; Statistical analysis in Additional file 3: Table S3)
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mouse is, in contrast to other APP-transgenic mice, the
only APP-transgenic mouse that shows neuron loss, syn-
apse loss, and dendritic degeneration [22, 24, 41]. Other
mouse models showing such signs of neurodegeneration
do not only express APP as the APP23 mouse but also
presenilin 1 or τ that can also be responsible for neuro-
degeneration [46, 47]. As such our study in APP23 mice
shows that morphological alterations of dendrites pre-
sumably caused by Aβ aggregates were subject of protec-
tion by immunotherapy but were not repaired once the
neurons were fallen victim to degeneration.
Our finding of soluble antibody-bound Aβ-containing
oligomers, protofibrils and fibrils as detected by immu-
noprecipitation in 5-month-old β1-treated APP23 mice
that were not seen in PBS-treated animals indicates that
β1-antibody treatment increases soluble Aβ aggregates.
The antibody may stabilize existing soluble aggregates
similar to blood Aβ [48, 49]. An enhancement of Aβ-
aggregation cannot be excluded. The lack of degener-
ation suggests that such soluble Aβ-IgG aggregates are
less pathogenic and may become subject of clearance.
No antibody-bound Aβ aggregates were found in the
blood of 5-month-old APP23 mice. The increase of
antibody-bound Aβ in the blood of 11-month-old β1-
treated APP23 mice but not in PBS-treated animals
most likely reflects stabilization of plasma Aβ as previ-
ously described [48, 49]. No modified forms of Aβ were
detected in the soluble fraction of 5- and 11-month old
mice and in the blood due to their respective low
concentrations or due to inefficient β1-antibody binding.
β1-treatment did not cause a shift in soluble andinsoluble Aβ aggregates in 11-month-old APP23 mice
exhibiting AβN3pE and pAβ. A possible explanation for
the lack of a treatment effect on Aβ aggregates in 11-
month-old APP23 mice may be the property of AβN3pE
and pAβ to stabilize Aβ aggregates in-vitro [18, 50] and,
in so doing, to preclude sufficient antibody treatment ef-
fects as shown here.
Since the APP23 mouse is a mouse model that showed
morphological signs of neurodegeneration with neuron
loss in CA1 [22], reduction of asymmetric synapse dens-
ities [23], and dendritic degeneration in commissural
neurons [24] this mouse model appears to be useful to
study morphological signs of Aβ-related neurotoxicity to
better understand the lack of improvement in anti-Aβ
treated patients [11, 14, 16]. In this context, our results
suggest that treatment attempts in already demented in-
dividuals exhibiting mature Aβ aggregates in the B-Aβ-
stage 3 indicated by AβN3pE and pAβ as its components
[17] may not be successful because 1. irreversible degen-
erative changes already took place and 2. mature Aβ ag-
gregates in B-Aβ stage 3 prevail [17], which were not
removed by β1-antibody treatment in APP23 mice as
described here. Accordingly, treatment strategies aimed
at protecting from Aβ maturation and early Aβ-related
neurodegenerative effects appear to be more attractive
than those targeting non-modified forms of Aβ including
oligomeric, protofibrillar and fibrillar aggregates.
Moreover, in human symptomatic AD cases in addition
to Aβ plaque pathology, there are already high amounts of
neurofibrillary tangles as well as severe neuron and synapse
loss. As such, the amount of brain damage at this stage of
the disease is significant. Given that most degenerating
Fig. 8 Effects of β1 antibody treatment in APP23 mice. Schematic representation of anti-Aβ (β1) treatment effects when applied before the onset
of neurodegeneration and Aβ plaque deposition (3–5 months) and when provided with prevalent pathology (7–11 months). Anti-Aβ antibody
treatment protected type 1 commissural neurons (Type 1) from dendritic degeneration accumulated antibody-bound oligomers, fibrils and
protofibrils in the soluble fraction containing Aβ. These effects were seen in B-Aβ stage 1. No positive effect on Type 1 commissural neurons was
found when β1-treatment was performed from 7 to 11 months of age. Moreover, plaque loads and biochemically detectable amounts of soluble,
dispersible, membrane-associated, and plaque-associated Aβ were similar in β1- and PBS-treated APP23 mice. Aβ aggregation at 11 months of
age corresponded to B-Aβ stage 3, i.e. fully mature, AD-related Aβ aggregates. Here, β1-treatment caused epitope modifications of Aβ aggregates
resulting in less β1- and B10AP-positive plaques in treated mice. Moreover, at 11 months of age presence of antibody-bound non-modified Aβ in
the serum was visible, whereas antibody-bound modified AβN3pE and pAβ were not seen in the blood plasma
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and that presence of Aβ plaques and neurofibrillary tangles
induces gliosis [52–56] compensation or reconstruction of
these lesions is very unlikely. Therefore, it is tempting tospeculate that early B-Aβ stage preclinical AD cases are
best suited to protect from or slow down progression of
the disease as shown in 3-months-old β1-treated APP23
mice sacrificed at 5 months of age. Findings in APP23-β1-
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cient protective effect of the β1-antibody is possible in the
initial stage of Aβ aggregation [28].
Effects of β1-antibody treatment on Aβ aggregates in
animals with preexisting pathology
β1-antibody treatment of APP23 mice between 7 and
11 months neither led to any improvement of neurodegen-
erative lesions nor to changes in the levels of soluble or the
insoluble types of Aβ aggregates or in Aβ plaque-loads
(Fig. 8). Modified forms of Aβ occurred in PBS- and
β1-treated APP23 mice in similar amounts (Fig. 8). Inter-
estingly, detection of Aβ plaques in β1-treated mice was at-
tenuated for staining with the β1-antibody and the B10AP
antibody fragments recognizing protofibril/ fibril-related
epitopes. In contrast, immunoprecipitation of soluble and
dispersible fractions with A11 and B10AP revealed similar
levels of soluble and dispersible Aβ oligomers, protofibrils
and fibrils. It is tempting to speculate that β1 antibody
bound to plaques to a certain extent blocked binding of
further β1 and B10AP antibodies. This finding is in agree-
ment with the binding of intravenously injected β1 anti-
body to preexisting plaques in APP23 mice [49].
However, immunoprecipitation of antibody-bound pep-
tides by incubating brain homogenates with protein G-
coated beads revealed no significant differences between
11-month-old immunized and non-immunized animals al-
though antibody-bound Aβ was immunoprecipitated in
the serum of β1-treated animals in contrast to PBS-treated
ones. The unexpected finding of IgG in plaques and bound
to Aβ aggregates in PBS-treated and β1-treated animals in
similar amounts may be explained by naturally occurring
autoantibodies that interact with amyloid plaques in
APP23 mice as previously demonstrated in AD patients
[57, 58]. Further evidence in favor of this interpretation is
provided by our finding that IgG was detected immunohis-
tochemically in plaques of PBS- and β1-treated animals in
similar amounts and pattern.
Aspects of Aβ maturation for Aβ-immunotherapy
The major finding of this study is that the maturation
stage of Aβ aggregates has impact on protective effects
of Aβ immunotherapy related to Aβ toxicity. If this effect
of the maturation stage on Aβ-immunotherapy seen in the
APP23 mouse would also apply for human AD this would
mean that immunotherapy should be started in early pre-
clinical stages of the disease exhibiting very few plaques
and B-Aβ stage 1. The non-favorable outcomes of recently
completed trials on passive immunization against Aβ with
bapineuzumab or solanezumab [13, 14] could be explained
as a logical consequence of the selection of patients with
early symptomatic AD, i.e. patients that very likely already
had B-Aβ stage 3 [17] indicative for advanced stage Aβ
pathology when they started the trial. Accordingly, it stillseems reasonable that Aβ-targeting immunotherapy trials
which include non-diseased individuals in a preclinical
phase of AD instead of symptomatic AD patients with late
stage pathology, may show a protective effect as shown
here in APP23 mice. However, in our mouse model we
only studied the effects of Aβ but not that of τ-pathology,
which prevails in human AD brain as well [59, 60] and ap-
pears capable of spreading into further brain regions even
without being triggered by Aβ [61].
Conclusions
Our results confirm previous studies that the protective
potential of passive Aβ immunization is much greater
than its disease modifying potential and demonstrate for
the first time that the maturation stage of the biochem-
ical Aβ aggregate composition, i.e. the B-Aβ stage, has
impact on Aβ-antibody treatment. As such, our results
point to an important role of the B-Aβ stage for design
of treatment strategies targeting Aβ.
Additional files
Additional file 1: Table S1. List of antibodies.
Additional file 2: Table S2. Types of commissural neurons traced with
DiI [24].
Additional file 3: Table S3. Statistical analysis.
Additional file 4: Figure S1. Neuronal and synaptic pathology: Effects
of β1 antibody treatment. No differences between PBS- and β1-treated
APP23 mice at 5 and 11 months of age in the densities of asymmetric (a)
and symmetric synapses in the frontocentral cortex (b) as well as in the
numbers of CA1 neurons in the hippocampus (c). Graphs represent mean
values (symbols) and standard errors (whiskers). (Statistical analysis in
Additional file 3: Table S3).
Additional file 5: Figure S2. Neuritic plaques: Effects of β1 antibody
treatment. APP-type neuritic plaques (arrows) are detectable in both
anti-Aβ (β1)- (a) and PBS-treated 11-month-old APP23 mice (b).
Calibration bar in b (valid for a, b) = 27.5 μm.
Additional file 6: Figure S3. IgG accumulation in plaques and cerebral
amyloid angiopathy and microglial activation: Effects of β1 antibody
treatment. Detection of microglial cells and mouse IgG in 5- and 11-month-
old β1- and PBS-treated APP23 mice. Mouse IgG comprises intrinsic mouse
IgG and the mouse-IgG antibody β1 used for treatment. Amyloid plaques in
11-month-old mice were detected by Aβ autofluorescence [35] whereas no
autofluorescent plaques were found in 5 month old animals. a–h: In
5-month-old APP23 mice no IgG and no amyloid material was observed in
both β1 and PBS-treated mice. Iba-1 immunostaining showed comparable
microglia pattern in both groups. i–t: Mouse IgG occurred in all plaques
(white and lucent arrows) and cerebral amyloid angiopathy (arrowheads)
affected vessels identified by amyloid autofluorescence in 11-month-old
APP23 mice. Plaque-associated microglial activation was observed in
β1- and PBS-treated mice in this age group (white arrows). Calibration bar in
a (valid for a-t) = 60 μm.
Additional file 7: Figure S4. IgG accumulation in plaques and cerebral
amyloid angiopathy and astroglial activation: Effects of β1 antibody
treatment. Detection of astrocytes and mouse IgG in 5- and 11-month-old
β1- and PBS-treated APP23 mice. Mouse IgG comprises intrinsic mouse IgG
and the mouse-IgG antibody β1 used for treatment. Amyloid plaques in
11-month-old mice were detected by Aβ autofluorescence [35] whereas no
autofluorescent plaques were found in 5 month old animals. a–h: In
5-month-old APP23 mice no IgG and no amyloid material was observed in
both β1 and PBS-treated mice. GFAP immunostaining showed comparable
Balakrishnan et al. Acta Neuropathologica Communications  (2015) 3:41 Page 15 of 17astroglia pattern in both groups. i–p: Mouse IgG occurred in all plaques
and cerebral amyloid angiopathy affected vessels identified by amyloid
autofluorescence in 11-month-old APP23 mice. Plaque-associated astrogliosis
was observed in β1- and PBS-treated mice in this age group. Calibration bar
in a (valid for a–l) = 80 μm; (m–p) = 70 μm.
Additional file 8: Figure S5. Soluble, dispersible, membrane-associated,
and plaque-associated Aβ in APP23 mice: Effects of β1 antibody
treatment. Full-length images of western blots corresponding to the
semiquantitative data shown in Fig. 4: Aβ, AβN3pE, and pAβ in the soluble,
dispersible, membrane-associated, and plaque-associated fraction of
brain homogenates of PBS- and β1-treated 5- and 11-month-old APP23
mice. No differences between PBS- and β1-treated animals except for
plaque-associated Aβ in 5-month-old mice: β1-treated animals exhibited
slightly more non-modified plaque-associated Aβ than non-treated mice.
AβN3pE and pAβ were not detected in brain homogenates of 5-month-old
APP23 mice but in the dispersible, membrane-associated, and plaque-
associated fraction of 11-month-old mice without differences in relation
to the treatment. The staining pattern of the blots may also exhibit
oligomeric Aβ aggregates. Since SDS-PAGE do not provide the native
oligomer pattern [37] we focused our data analysis on the monomer
band that has been demonstrated to reflect best the Aβ content when
performing SDS-PAGE analysis [23].
Additional file 9: Figure S6. Soluble and dispersible (insoluble) Aβ
fibrils/protofibrils and non-fibrillar oligomers in APP23 mice: Effects of β1
antibody treatment. Full-length images of western blots corresponding
to the semiquantitative data shown in Fig. 5: Western blots from soluble
and dispersible non-fibrillar oligomers immunoprecipitated with A11 and
protofibrils and fibrils immunoprecipitated with B10AP from the
respective brain homogenate fractions in 5- and 11-month-old β1- and
PBS-treated APP23 mice. 5-month-old β1-treated mice exhibited soluble
Aβ-oligomers, protofibrils and fibrils that were not seen in PBS-treated
controls. Although dispersible Aβ oligomers, protofibrils and fibrils were
detected in 5-month-old APP23 mice as well there were no differences
between β1- and PBS-treated mice. AβN3pE and pAβ were not seen in 5-
month-old mice. No differences in soluble and dispersible Aβ aggregates
were observed between 11-month-old β1- and PBS-treated mice. AβN3pE
and pAβ were not detectable in soluble oligomers, protofibrils and fibrils as
well as in dispersible oligomers at both ages whereas dispersible fibrils and
protofibrils exhibited both AβN3pE and pAβ.
Additional file 10: Figure S7. Immunoglobulin-bound Aβ detected
in oligomers, protofibrils and fibrils in APP23 mice: Effects of β1 antibody
treatment. Full-length images of western blots corresponding to
the semiquantitative data shown in Fig. 6. Western blots after
immunoprecipitation of immunoglobulin-bound Aβ by precipitation of
antibodies with protein G-coated magnetic beads. Subsequent western
blot analysis with anti-Aβ1–17 revealed antibody-bound Aβ in the dispersible
fraction of both β1- and PBS-treated mice at both ages. In 5-month-old
β1-treated APP23 mice antibody-bound Aβ was found in the soluble
fraction whereas no antibody-bound Aβ was precipitated in PBS-treated
animals. At 11-months of age both, β1 and PBS-treated animals
exhibited antibody bound soluble Aβ in similar amounts. Antibody-bound
AβN3pE was not observed whereas 11-month-old (but not 5-month-old)
APP23 mice showed similar amounts of dispersible antibody-bound pAβ.
No soluble antibody-bound pAβ was seen.
Additional file 11: Figure S8. Serum Aβ immunoprecipitated by
protein-G bound antibodies in APP23 mice: Effects of β1 antibody
treatment. Full-length images of western blots corresponding to the
semiquantitative data shown in Fig. 7. Western blot analysis of blood
serum for Aβ and immunoprecipitation of intrinsic serum antibodies by
incubation with protein G-coated magnetic beads and with subsequent
western blotting for Aβ. Aβ was only seen in 5-month-old β1-treated APP23
mice after antibody-immunoprecipitation and detection with anti-Aβ1–17
(6E10). AβN3pE and pAβ were not found in these precipitates. PBS-treated
and 5-month-old mice did not exhibit detectable amounts of Aβ.
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